https://www.selleckchem.com/pr....oducts/colivelin.htm
Thirty-four of the 1433 patients with mCRPC attending the participating centres (2.3%) developed SARS-CoV-2 infection, 22 (64.7%) of whom were hospitalised. Most of the patients were symptomatic, the most frequent symptoms being fever (70.6%), dyspnoea (61.8%), cough (52.9%)and fatigue (38.2%). After a median follow-up of 21 days (interquartile range 13-41), 13 patients had died (38.2%), 17 recovered (50.0%)and four (11.7%) were still infected. The number of treatments previously administered for mCRPC had a significant impact on mort